IP Library › Granted Patent US 12,257,416
Granted Patent B1
US 12,257,416 · App. 18/883,857 · Granted Mar 25, 2025

Fluid therapy based on sodium excretion, and associated systems, devices, and methods

Inventors: Andrew V. Halpert (Brookline, MA); Antony Jonathan Fields (San Francisco, CA); Jeffrey Testani (New Haven, CT)
Assignee: Reprieve Cardiovascular, Inc.
A61M5/1407A61B5/208A61B5/4839A61M5/1723
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,257,416
App. No.
18/883,857
Filed
Sep 12, 2024
Granted
Mar 25, 2025
Kind
B1
Art Unit
3783
USPC
604/131
Abstract

This present disclosure relates to fluid therapy based on sodium excretion, and associated systems, devices, and methods. Exemplary methods can include receiving a sodium excretion input for the patient; receiving a urine output rate; determining an adjusted urine output rate based on the sodium excretion input and the urine output rate; and providing fluid therapy based on the adjusted urine output rate. By determining the amount and/or rate of the infused diuretic and/or hydration fluid based on a patient's actual sodium excretion levels, embodiments of the present technology can optimize and/or customize all or a subset of a diuretic therapy to an individual patient's physiology.

Claims (51)

1. A fluid therapy system, comprising:

a diuretic source configured to provide a diuretic to a patient;

a hydration fluid source configured to provide a hydration fluid to the patient; and

a controller, wherein the controller is configured to—

during a first time period, provide fluid therapy based on an assumed sodium excretion input; and

during a second time period after the first time period—

obtain a sodium excretion input for the patient;

determine a sodium output rate based at least in part on the sodium excretion input; and

based on the sodium output rate, (i) cause the diuretic to be administered to the patient at one or more diuretic dosage rates and (ii) cause the hydration fluid to be administered to the patient at one or more hydration rates to produce a net fluid loss in the patient.

2. The fluid therapy system of claim 1 , further comprising a urine measurement device configured to measure urine output of the patient, wherein the controller is further configured to determine the sodium output rate based at least in part on the sodium excretion input and a urine output rate obtained via the urine measurement device.

3. The fluid therapy system of claim 1 , wherein the controller is further configured to:

compare the sodium excretion input with one or more sodium output rate thresholds associated with the administration of the hydration fluid and/or the diuretic to the patient; and

cause the diuretic and/or the hydration fluid to be administered and/or cause an adjustment to the administration of the diuretic and/or the hydration fluid based at least in part on the comparison.

4. The fluid therapy system of claim 1 , wherein the sodium excretion input includes a conductivity of the patient's urine.

5. The fluid therapy system of claim 1 , wherein the sodium excretion input includes a concentration of sodium in the patient's urine.

6. The fluid therapy system of claim 1 , wherein:

before receiving the sodium excretion input, the controller is configured to provide the hydration fluid at a hydration fluid infusion rate; and

after receiving the sodium excretion input, the controller is configured to adjust the hydration fluid infusion rate based on the sodium output rate.

7. The fluid therapy system of claim 1 , wherein:

before receiving the sodium excretion input, the controller is configured to provide the diuretic at a diuretic dosage rate; and

after receiving the sodium excretion input, the controller is configured to adjust the diuretic dosage rate based on the sodium output rate.

8. The fluid therapy system of claim 1 , further comprising a user interface, wherein the controller is configured to obtain the sodium excretion input for the patient from a user input via the user interface.

9. The fluid therapy system of claim 1 , further comprising a sensor configured to detect a sodium concentration in urine output from the patient, wherein the controller is configured to obtain the sodium excretion input for the patient based at least in part on the sodium concentration detected via the sensor.

10. The fluid therapy system of claim 1 , wherein the assumed sodium excretion input is an assumed sodium excretion based at least in part on a measured urine output rate for the patient and an assumed concentration of sodium in the patient's urine.

11. The fluid therapy system of claim 10 , wherein the assumed concentration of sodium is 140 mmol/L.

12. The fluid therapy system of claim 1 , wherein the controller is configured to obtain a sodium loss based on the sodium output rate and cause an amount the hydration fluid to be administered to replace a percentage of the sodium loss.

13. The fluid therapy system of claim 12 , wherein the percentage is up to 50% of the sodium loss.

14. A method for providing fluid therapy to a patient, the method comprising:

during a first time period, causing a hydration fluid and/or a diuretic to be administered to the patient at one or more rates that are based at least in part on an assumed sodium excretion input for the patient; and

during a second time period after the first time period—

obtaining a sodium excretion input for the patient;

determining a sodium output rate based at least in part on the sodium excretion input; and

based on the sodium output rate, (i) causing the diuretic to be administered to the patient at one or more diuretic dosage rates and (ii) causing the hydration fluid to be administered to the patient at one or more hydration rates to produce a net fluid loss in the patient.

15. The method of claim 14 , further comprising obtaining a urine output rate for the patient, wherein determining the sodium output rate includes determining the sodium output rate based at least in part on the sodium excretion input and the urine output rate.

16. The method of claim 14 , wherein determining the sodium excretion input includes determining a conductivity of the patient's urine.

17. The method of claim 14 , wherein obtaining the sodium excretion input includes obtaining a concentration of sodium in the patient's urine.

18. The method of claim 14 , wherein obtaining the sodium excretion input includes obtaining the sodium excretion input from a user via a user interface.

19. The method of claim 14 , wherein obtaining the sodium excretion input incudes obtaining the sodium excretion input via a sensor configured to detect a level of sodium in the patient's urine.

20. The method of claim 14 , wherein obtaining the sodium excretion input includes:

collecting urine within a collection container of a fluid therapy system;

removing a urine sample from the urine collected within the collection container;

measuring a concentration of sodium in the urine sample; and

causing a processor of the fluid therapy system to obtain the concentration.

21. The method of claim 20 wherein causing the processor to obtain the concentration includes inputting the concentration via a user interface of the fluid therapy system.

22. The method of claim 14 , wherein the assumed sodium excretion input is an assumed sodium excretion based at least in part on an obtained urine output rate for the patient and an assumed concentration of sodium in the patient's urine.

23. The method of claim 14 wherein the first time period is up to 6 hours.

24. The method of claim 14 wherein the first time period includes an amount of time before the patient has output a predetermined quantity of urine.

25. The method of claim 14 wherein the first time period includes an amount of time before the patient has output at least 1 liter of urine.

26. The method of claim 14 wherein (i) causing the diuretic to be administered to the patient at the one or more diuretic dosage rates and/or (ii) causing the hydration fluid to be administered to the patient at the one or more hydration rates includes causing the diuretic and/or the hydration fluid to be administered to produce a net sodium loss in the patient.

27. The method of claim 14 wherein causing the hydration fluid to be administered includes replacing a percentage of the sodium lost from the patient via urine during fluid therapy.

28. The method of claim 27 , wherein the percentage is up to 50% of the sodium lost from the patient via urine during fluid therapy.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2024
From: HALPERT, ANDREW V.; FIELDS, ANTONY JONATHAN; TESTANI, JEFFREY
To: REPRIEVE CARDIOVASCULAR, INC.
Reel/Frame 069510/0115 →
Continuity (2)
Provisional Application 63680042 · Aug 6, 2024
Provisional Application 63582218 · Sep 12, 2023
References Cited (309)
US 3954010A · Hilblom · 1976 [cited by applicant]
US 4132644A · Kolberg · 1979 [cited by applicant]
US 4146029A · Ellinwood, Jr. · 1979 [cited by applicant]
US 4204957A · Weickhardt · 1980 [cited by applicant]
US 4216462A · McGrath et al. · 1980 [cited by applicant]
US 4229299A · Savitz et al. · 1980 [cited by applicant]
US 4261360A · Perez · 1981 [cited by applicant]
US 4275726A · Schael · 1981 [cited by applicant]
US 4291692A · Bowman et al. · 1981 [cited by applicant]
US 4343316A · Jespersen · 1982 [cited by applicant]
US 4411649A · Kamen · 1983 [cited by applicant]
US 4448207A · Parrish · 1984 [cited by applicant]
US 4449538A · Corbitt et al. · 1984 [cited by applicant]
US 4504263A · Steuer et al. · 1985 [cited by applicant]
US 4658834A · Blankenship et al. · 1987 [cited by applicant]
US 4712567A · Gille et al. · 1987 [cited by applicant]
US 4728333A · Masse et al. · 1988 [cited by applicant]
US 4728433A · Buck et al. · 1988 [cited by applicant]
US 4813925A · Anderson, Jr. et al. · 1989 [cited by applicant]
US 4923598A · Schal · 1990 [cited by applicant]
US 4994026A · Fecondini · 1991 [cited by applicant]
US 5038109A · Goble · 1991 [cited by examiner]
US 5098379A · Conway et al. · 1992 [cited by applicant]
US 5176148A · Wiest et al. · 1993 [cited by applicant]
US 5179862A · Lynnworth · 1993 [cited by applicant]
US 5207642A · Orkin et al. · 1993 [cited by applicant]
US 5573506A · Vasko · 1996 [cited by applicant]
US 5586973A · Lemaire et al. · 1996 [cited by applicant]
US 5709670A · Vancaillie et al. · 1998 [cited by applicant]
US 5722947A · Jeppsson et al. · 1998 [cited by applicant]
US 5769087A · Westphal et al. · 1998 [cited by applicant]
US 5814009A · Wheatman · 1998 [cited by applicant]
US 5891051A · Han et al. · 1999 [cited by applicant]
US 5910252A · Truitt et al. · 1999 [cited by applicant]
US 5916153A · Rhea, Jr. · 1999 [cited by applicant]
US 5916195A · Eshel et al. · 1999 [cited by applicant]
US 5981051A · Motegi et al. · 1999 [cited by applicant]
US 5984893A · Ward · 1999 [cited by applicant]
US 6010454A · Arieff et al. · 2000 [cited by applicant]
US 6171253B1 · Bullister et al. · 2001 [cited by applicant]
US 6231551B1 · Barbut · 2001 [cited by applicant]
US 6272930B1 · Crozafon · 2001 [cited by applicant]
US 6514226B1 · Levin et al. · 2003 [cited by applicant]
US 6531551B2 · Ohno et al. · 2003 [cited by applicant]
US 6537244B2 · Paukovits et al. · 2003 [cited by applicant]
US 6554791B1 · Cartledge et al. · 2003 [cited by applicant]
US 6640649B1 · Paz et al. · 2003 [cited by applicant]
US 6740072B2 · Starkweather et al. · 2004 [cited by applicant]
US 6752779B2 · Paukovits et al. · 2004 [cited by applicant]
US 6796960B2 · Cioanta et al. · 2004 [cited by applicant]
US 6827702B2 · Lebel et al. · 2004 [cited by applicant]
US 6942637B2 · Cartledge et al. · 2005 [cited by applicant]
US 7029456B2 · Ware et al. · 2006 [cited by applicant]
US 7044002B2 · Ericson et al. · 2006 [cited by applicant]
US 7086615B2 · Joseph · 2006 [cited by applicant]
US 7137964B2 · Flaherty · 2006 [cited by applicant]
US 7278983B2 · Ireland et al. · 2007 [cited by applicant]
US 7727222B2 · Da Silva · 2010 [cited by applicant]
US 7736354B2 · Gelfand · 2010 [cited by applicant]
US 7739921B1 · Babcock · 2010 [cited by applicant]
US 7758562B2 · Gelfand · 2010 [cited by applicant]
US 7758563B2 · Gelfand · 2010 [cited by applicant]
US 7837667B2 · Gelfand · 2010 [cited by applicant]
US 7938817B2 · Gelfand · 2011 [cited by applicant]
US 8007460B2 · Gelfand · 2011 [cited by applicant]
US 8075513B2 · Rudko et al. · 2011 [cited by applicant]
US 8233957B2 · Merz et al. · 2012 [cited by applicant]
US 8444623B2 · Gelfand · 2013 [cited by applicant]
US 8556846B2 · O'Mahony et al. · 2013 [cited by applicant]
US 8714030B1 · Liu · 2014 [cited by applicant]
US 9526833B2 · Gelfand et al. · 2016 [cited by applicant]
US 10045734B2 · Da Silva · 2018 [cited by applicant]
US 10537281B2 · Thompson et al. · 2020 [cited by applicant]
US 10639419B2 · Halpert · 2020 [cited by applicant]
US 10881774B2 · Halpert · 2021 [cited by applicant]
US 11064939B2 · Da Silva · 2021 [cited by applicant]
US 11213621B2 · Halpert · 2022 [cited by applicant]
US 11357446B2 · Levin et al. · 2022 [cited by applicant]
US 11633137B2 · Conley et al. · 2023 [cited by applicant]
US 11696985B2 · Halpert · 2023 [cited by applicant]
US 11950925B2 · Levin · 2024 [cited by applicant]
US 11986302B2 · Conley et al. · 2024 [cited by applicant]
US 11992332B2 · Da Silva · 2024 [cited by applicant]
US 20010029340A1 · Mault et al. · 2001 [cited by applicant]
US 20020025597A1 · Matsuda · 2002 [cited by applicant]
US 20020072647A1 · Schock et al. · 2002 [cited by applicant]
US 20020107536A1 · Hussein · 2002 [cited by applicant]
US 20020151834A1 · Utterberg · 2002 [cited by applicant]
US 20020161314A1 · Sarajarvi · 2002 [cited by applicant]
US 20030040700A1 · Hickle · 2003 [cited by applicant]
US 20030048185A1 · Citrenbaum et al. · 2003 [cited by applicant]
US 20030048432A1 · Jeng et al. · 2003 [cited by applicant]
US 20030114786A1 · Hiller et al. · 2003 [cited by applicant]
US 20040025597A1 · Ericson et al. · 2004 [cited by applicant]
US 20040059295A1 · Cartledge et al. · 2004 [cited by applicant]
US 20040081585A1 · Reid · 2004 [cited by applicant]
US 20040087894A1 · Flaherty · 2004 [cited by applicant]
US 20040122353A1 · Shahmirian et al. · 2004 [cited by applicant]
US 20040133187A1 · Hickle · 2004 [cited by applicant]
US 20040163655A1 · Gelfand et al. · 2004 [cited by applicant]
US 20040167415A1 · Gelfand · 2004 [cited by applicant]
US 20040167464A1 · Ireland et al. · 2004 [cited by applicant]
US 20040176703A1 · Christensen et al. · 2004 [cited by applicant]
US 20040193328A1 · Zaitsu et al. · 2004 [cited by applicant]
US 20040243075A1 · Harvie · 2004 [cited by applicant]
US 20050027254A1 · Vasko · 2005 [cited by applicant]
US 20050065464A1 · Talbot et al. · 2005 [cited by applicant]
US 20050085760A1 · Ware et al. · 2005 [cited by applicant]
US 20060052764A1 · Gelfand et al. · 2006 [cited by applicant]
US 20060064053A1 · Bollish et al. · 2006 [cited by applicant]
US 20060100743A1 · Townsend et al. · 2006 [cited by applicant]
US 20060184084A1 · Ware et al. · 2006 [cited by applicant]
US 20060235353A1 · Gelfand et al. · 2006 [cited by applicant]
US 20060253064A1 · Gelfand et al. · 2006 [cited by applicant]
US 20060270971A1 · Gelfand et al. · 2006 [cited by applicant]
US 20070055198A1 · O'Mahony et al. · 2007 [cited by applicant]
US 20070088333A1 · Levin et al. · 2007 [cited by applicant]
US 20080027409A1 · Rudko et al. · 2008 [cited by applicant]
US 20080033394A1 · Gelfand et al. · 2008 [cited by applicant]
US 20080051764A1 · Dent et al. · 2008 [cited by applicant]
US 20080171966A1 · Rudko et al. · 2008 [cited by applicant]
US 20080221512A1 · Da Silva et al. · 2008 [cited by applicant]
US 20090054745A1 · Jennewine · 2009 [cited by applicant]
US 20090062730A1 · Woo · 2009 [cited by applicant]
US 20100133510A1 · Kim et al. · 2010 [cited by applicant]
US 20100185175A1 · Kamen · 2010 [cited by examiner]
US 20100280443A1 · Gelfand et al. · 2010 [cited by applicant]
US 20100280444A1 · Gelfand et al. · 2010 [cited by applicant]
US 20100286559A1 · Paz et al. · 2010 [cited by applicant]
US 20100312039A1 · Quirico · 2010 [cited by applicant]
US 20110046514A1 · Greenwald et al. · 2011 [cited by applicant]
US 20110046516A1 · Paz et al. · 2011 [cited by applicant]
US 20110120231A1 · Berger · 2011 [cited by applicant]
US 20110196304A1 · Kramer et al. · 2011 [cited by applicant]
US 20110218411A1 · Keenan · 2011 [cited by applicant]
US 20110288524A1 · Gelfand et al. · 2011 [cited by applicant]
US 20120078137A1 · Mendels · 2012 [cited by applicant]
US 20120259308A1 · Gelfand · 2012 [cited by applicant]
US 20130104667A1 · Koyano · 2013 [cited by applicant]
US 20130235691A1 · Volker · 2013 [cited by applicant]
US 20130261412A1 · Reed · 2013 [cited by applicant]
US 20130274705A1 · Burnes et al. · 2013 [cited by applicant]
US 20140031787A1 · Burnes et al. · 2014 [cited by applicant]
US 20140073973A1 · Sexton · 2014 [cited by applicant]
US 20140228755A1 · Darrah et al. · 2014 [cited by applicant]
US 20140260600A1 · Rike · 2014 [cited by applicant]
US 20140366641A1 · Jedema et al. · 2014 [cited by applicant]
US 20150105694A1 · Mahajan · 2015 [cited by applicant]
US 20150233749A1 · Wang et al. · 2015 [cited by applicant]
US 20150258277A1 · Halpert · 2015 [cited by applicant]
US 20160051176A1 · Ramos et al. · 2016 [cited by applicant]
US 20160051750A1 · Tsoukalis · 2016 [cited by applicant]
US 20160136356A1 · Ribble et al. · 2016 [cited by applicant]
US 20170016755A1 · Boussange et al. · 2017 [cited by applicant]
US 20170052056A1 · Yamasaki et al. · 2017 [cited by applicant]
US 20170290974A1 · Tsoukalis · 2017 [cited by applicant]
US 20180071455A9 · Halpert · 2018 [cited by applicant]
US 20180110455A1 · Chang et al. · 2018 [cited by applicant]
US 20180177945A1 · Sims et al. · 2018 [cited by applicant]
US 20180245967A1 · Parker et al. · 2018 [cited by applicant]
US 20180280620A1 · Reichthalhammer · 2018 [cited by applicant]
US 20190001057A1 · Tsoukalis · 2019 [cited by applicant]
US 20190038833A1 · Pirazzoli et al. · 2019 [cited by applicant]
US 20190046723A1 · Halpert · 2019 [cited by examiner]
US 20190262532A1 · Oh et al. · 2019 [cited by applicant]
US 20190321588A1 · Burnett · 2019 [cited by applicant]
US 20200230351A1 · Kelly et al. · 2020 [cited by applicant]
US 20200324044A1 · Gylland et al. · 2020 [cited by applicant]
US 20200360604A1 · Kolko et al. · 2020 [cited by applicant]
US 20200284234A1 · Niland · 2020 [cited by applicant]
US 20200405955A1 · Shah et al. · 2020 [cited by applicant]
US 20210077007A1 · Jouret et al. · 2021 [cited by applicant]
US 20210085853A1 · Chen et al. · 2021 [cited by applicant]
US 20210128815A1 · Byrne et al. · 2021 [cited by applicant]
US 20210162188A1 · Cui · 2021 [cited by applicant]
US 20210169408A1 · Levin · 2021 [cited by applicant]
US 20210170084A1 · Zacharia · 2021 [cited by applicant]
US 20210196880A1 · O'Mahony et al. · 2021 [cited by applicant]
US 20210236727A1 · Levin et al. · 2021 [cited by applicant]
US 20210244381A1 · Sweeney et al. · 2021 [cited by applicant]
US 20210260306A1 · Gravenstein et al. · 2021 [cited by applicant]
US 20210283357A1 · Leonard · 2021 [cited by applicant]
US 20210298653A1 · Woodward et al. · 2021 [cited by applicant]
US 20210369959A1 · Abal et al. · 2021 [cited by applicant]
US 20220152302A1 · Halpert · 2022 [cited by applicant]
US 20220273213A1 · Sokolov · 2022 [cited by applicant]
US 20220288362A1 · Porter et al. · 2022 [cited by applicant]
US 20220296406A1 · Keelen · 2022 [cited by applicant]
US 20220313158A1 · Levin et al. · 2022 [cited by applicant]
US 20220330866A1 · Conley et al. · 2022 [cited by applicant]
US 20220330867A1 · Conley et al. · 2022 [cited by applicant]
US 20220339622A1 · Halpert · 2022 [cited by applicant]
US 20230010793A1 · Testani · 2023 [cited by applicant]
US 20230068431A1 · Erbey, II et al. · 2023 [cited by applicant]
US 20230414871A1 · Halpert · 2023 [cited by applicant]
US 20240260874A1 · Halpert · 2024 [cited by applicant]
EP 0258690 · 1998 [cited by applicant]
EP 1986007 · 2008 [cited by applicant]
EP 3278833 · 2018 [cited by applicant]
EP 4108171 · 2022 [cited by applicant]
GB 2560580 · 2018 [cited by applicant]
JP 2008110150 · 2008 [cited by applicant]
JP A2011520549 · 2011 [cited by applicant]
JP A2017536857 · 2017 [cited by applicant]
KR 1020220035738 · 2022 [cited by applicant]
WO WO1996016685 · 1996 [cited by applicant]
WO WO1996028209 · 1996 [cited by applicant]
WO WO1997016220 · 1997 [cited by applicant]
WO WO1999006087 · 1999 [cited by applicant]
WO WO2005102441 · 2005 [cited by applicant]
WO WO2006041496 · 2006 [cited by applicant]
WO WO2009029899 · 2009 [cited by applicant]
WO WO2013154783 · 2013 [cited by applicant]
WO WO2014022422 · 2014 [cited by applicant]
WO WO2015142617 · 2015 [cited by applicant]
WO WO2016103256 · 2016 [cited by applicant]
WO WO2018114794 · 2018 [cited by applicant]
WO WO2019222485 · 2019 [cited by applicant]
WO WO2020033752 · 2020 [cited by applicant]
WO 2021205345 · 2021 [cited by applicant]
WO WO2022219578 · 2022 [cited by applicant]
U.S. Appl. No. 16/544,975, filed Aug. 20, 2019, Levin. [cited by applicant]
U.S. Appl. No. 18/595,182, filed Mar. 4, 2024, Levin. [cited by applicant]
U.S. Appl. No. 18/637,340, filed Apr. 16, 2024, Conley et al. [cited by applicant]
U.S. Appl. No. 18/641,241, filed Apr. 19, 2024, Da Silva. [cited by applicant]
U.S. Appl. No. 18/883,857, filed Sep. 12, 2024, Halpert. [cited by applicant]
“2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure—Web Addenda,” European Heart Journal, 17 pages. [cited by applicant]
Adams et al., “Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline,” Journal of Cardiac Failure, vol. 12, No. 1, 2006, pp. 10-38. [cited by applicant]
Adaptec Medical Devices, “Ongoing Access to Real-Time And Accurate Monitoring of Urine Output Could Improve Management of Critically Ill Patients,” Clinical Literature Review, (2016) 8 pages. [cited by applicant]
Allen et al., “Continuous Versus Bolus Dosing of Furosemide for Patients Hospitalized for Heart Failure,” American Journal of Cardiology, 105(12):1794-1794, 2010. [cited by applicant]
Baliga, “Diuretic Therapy for Heart Failure Patients,” American College of Cardiology, 75:1178-1195, 2020. [cited by applicant]
Bart et al., “Ultrafiltration in Decompensated Heart Failure With Cardiorenal Syndrome”, The New England Journal of Medicine, Dec. 13, 2012, 9 pages, Massachusetts Medical Society. [cited by applicant]
Bell et al., “Risk of Postoperative Acute Kidney Injury in Patients Undergoing Orthopaedic Surgery—Development and Validation of Risk score and Effect of Acute Kidney Injury on Survival: Observational Cohort Study,” BMJ… [cited by applicant]
Bouman et al., “Red Blood Cell Transfusion and Furosemide in Cardiac Surgery: Friend and Foe?” The Netherlands Journal of Medicine, Dec. 2012, vol. 70, No. 10, 3 pages. [cited by applicant]
Brater, “Diuretic Therapy,” New England Journal of Medicine, 339:387-395, 1998. [cited by applicant]
Brezis et al., Hypoxia of the Renal Medulla—Its Implications for Disease, New England Journal of Medicine, vol. 322, No. 10, Mar. 9, 1995, 9 pages. [cited by applicant]
Briguori et al., “Renal Insufficiency After Contrast Media Administration Trial II (Remedial II): RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury”, Circulation, Journal of the American H… [cited by applicant]
Conradds, “Sensitivity and Positive Predictive Value of Implantable Intrathoracic Impedance Monitoring as a Predictor of Heart Failure Hospitalizations: The SENSE-HF Trial,” European Heart Journal (2011) 32, 2266-2273, … [cited by applicant]
Cosgrove III et al., “Automated Control Postoperative Hypertension: a Prospective Randomized Multicenter Study,” 1989 by The Society of Thoracic Surgeons, 6 pages. [cited by applicant]
Dorval et al., “Feasibility Study of the RenalGuard™ Balanced Hydration System: a Novel Strategy for the Prevention of Contrast-Induced Nephropathy in High Risk Patients”, International Journal of Cardiology, 2011, 5 pa… [cited by applicant]
Doty et al., Effect of Increased Renal Venous Pressure on Renal Function, The Journal of Trauma: Injury, Infection and Critical Care, vol. 47, No. 6, Dec. 1999, 4 pages. [cited by applicant]
Edelson et al., Pharmacokinetics of Iohexol, a New Nonionic Radiocontrast Agent, in Humans, Journal of Pharmaceutical Sciences, vol. 73, No. 7, Jul. 1984, 3 pages. [cited by applicant]
Ellison et al., “Diuretic Treatment in Heart Failure,” New England Journal of Medicine, 377:1964-1975, 2017. [cited by applicant]
Farcy, “Review: Pitfalls in Using Central Venous Pressure as a Marker of Fluid Responsiveness,” Emergency Medicine. Jan. 2016;48(1):18-28, 15 pages. [cited by applicant]
Farkas, “Deresuscitation: Dominating the Diuresis,” The Internet Book of Critical Care, 43 pages, 2020. [cited by applicant]
Felker et al., “Diuretic Strategies in Patients With Acute Decompensated Heart Failure”, The New England Journal of Medicine, Mar. 3, 2011, vol. 364, No. 9, 9 pages. [cited by applicant]
Furutani et al., “An Automatic Control System of the Blood Pressure of Patients Under Surgical Operation,” International Journal of Control, Automation, and Systems, vol. 2, No. 1, Mar. 2004, pp. 39-54. [cited by applicant]
Gheorghiade et al., “Current Medical Therapy for Advanced Heart Failure,” American Heart Journal, Jun. 1998, pp. S231-S248. [cited by applicant]
Gloor, James M. and Vincente E. Torres, Reflux and Obstructive Nephropathy, Atlas of Diseases of the Kidney, on-line edition, vol. Two, Section I, Ch. 8, pp. 8.1-8.25, 1999, 27 pages. [cited by applicant]
Goren et al., “Perioperative Acute Kidney Injury,” British Journal of Anaesthesia, 2015, 12 pages. [cited by applicant]
Hasselblad et al., “Relation Between Dose of Loop Diuretics and Outcomes in a Heart Failure Population: Results of the ESCAPE Trial”, European Journal of Heart Failure, 9(10):1064-1069, 2007. [cited by applicant]
Heyman et al., Pathophysiology of Radiocontrast Nephropathy: a Role for Medullary Hypoxia, Investigative Radiology, vol. 34, No. 11, Nov. 1999, 7 pages. [cited by applicant]
Hvistendahl et al., Renal Hemodynamic Response to Gradated Ureter Obstruction in the Pig, Nephron 1996, 74:168-74, 7 pages. [cited by applicant]
Jin et al., “Intensive Monitoring of Urine Output is Associated With Increased Detection of Acute Kidney Injury and Improved Outcomes,” Chest Journal—Original Research Critical Care, 152#5, pp. 972-979 (Nov. 2017) 8 pag… [cited by applicant]
Josephs et al., “Perioperative Risk Assessment, Prevention, and Treatment of Acute Kidney Injury,” International Anesthesiology Clinics, vol. 47, No. 4, www.anesthesiaclinics.com, pp. 89-105. [cited by applicant]
Kalantari, “Assessment of Intravascular Volume Status and Volume Responsiveness in Critically Ill Patients,” Kidney International (2013) 83, 1017-1028 (Jan. 9, 2013) 12 pages. [cited by applicant]
Kolh, “Renal Insufficiency After Cardiac Surgery: a Challenging Clinical Problem,” European Heart Journal, 2009, pp. 1824-1827. [cited by applicant]
Lara, “Accurate Monitoring of Intravascular Fluid Volume: a Novel Application of Intrathoracic Impedance Measures For the Guidance of Volume Reduction Therapy,” IJC Heart & Vasculature, 8 (2015) pp. 47-51, 5pages. [cited by applicant]
Lassnigg et al., “Lack of Renoprotective Effects of Dopamine and Furosemide During Cardiac Surgery,” J. Am Soc Nephrol, 2000, pp. 97-104. [cited by applicant]
Lelarge et al., Acute Unilateral Renal Failure and Contralateral Ureteral Obstruction, American Journal of Kidney Diseases, vol. XX, No. 3, Sep. 1992, 3 pages. [cited by applicant]
Lenihan et al., “Trends in Acute Kidney Injury, Associated Use of Dialysis and Mortality After Cardiac Surgery, 1999 to 2008,” Ann Thorac Surg. 2013, 17 pages. [cited by applicant]
Levin et al. High-volume diuresis with matched maintenance of intravascular volume may prevent contrast-induced nephropathy in post-transplant patients with moderate-severe baseline renal impairment, Cardiovascular Reva… [cited by applicant]
Lloyd-Jones et al., “Heart Disease and Stroke Statistics—2009 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee”, Circulation, Journal of the American Heart Ass… [cited by applicant]
Magder et al., “The Clinical Role of Central Venous Pressure Measurements”, Journal of Intensive Care Medicine 22(1); 207, 8 pages. [cited by applicant]
Marenzi et al., “Prevention of Contrast Nephropathy by Furosemide With Matched Hydration,” JACC: Cardiovascular Interventions, 5(1):90-97, 2011. [cited by applicant]
Marenzi et al.. “Prevention of Contrast Nephropathy by Furosemide With matched Hydration. The MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) T… [cited by applicant]
Mawer et al., “Value of Forced Diuresis in Acute Barbiturate Poisoning”, Jun. 29, 1968, British Medical Journal, 2, 4 pages. [cited by applicant]
Mayo Clinic, “Creatinine Test”, Mayo Foundation for Medical Education and Research (MFMER) (downloaded Aug. 16, 2018). [cited by applicant]
Meersch et al., “Perioperative Acute Kidney Injury: An Under-Recognized Problem,” vol. 125, No. 4, www.anesthesia-analgesia.org, Oct. 2017, pp. 1223-1232. [cited by applicant]
Mendeley et al., “Furosemide”, Science Direct, 5 pages, 2016. [cited by applicant]
Oh et al., “Loop Diuretics in Clinical Practice,” Review: Electrolyte Blood Press, 13(1): 5 pages, 2015. [cited by applicant]
Olivero et al., “Acute Kidney Injury After Cardiovascular Surgery: an Overview,” debakeyheartcenter.com/journal, 2012, pp. 31-36. [cited by applicant]
Otero, “A New Device to Automate the Monitoring of Critical Patients' Urine Output”, Hindawi Publishing Corp, BioMed Research Int'l, vol. 2014, Article ID 587593, 8 pages. [cited by applicant]
Palazzuli et al. “Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial,” Critical Care 18, 2014. [cited by applicant]
Paterna et al., “Changes in Brain Natriuretic Peptide Levels and Bioelectrical Impedance Measurements After Treatment With High-Dose Furosemide and Hypertonic Saline Solution Versus High-Dose Furosemide Alone in Refract… [cited by applicant]
Pederson et al., Renal Water and Sodium Handling During Gradated Unilateral Ureter Obstruction, Scand J. Urol Nephrol, 2002, 36:163-72, 11 pages. [cited by applicant]
Prandota et al., “Pharmacokinetics and metabolism of furosemide in man,” European Journal of Drug Metabolism and Pharmcokinetics, 1(4): 5 pages, 1976. [cited by applicant]
Rihal et al., Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention, Circulation, May 14, 2002, 6 pages. [cited by applicant]
Rosamilia et al., Electromotive Drug Administration of Lidocaine and Dexamethasone Followed by Cystodistension in Women with Interstitial Cystitis, International Urogyecologyl Journal, Pelvic Floor Dysfunction 1997; 8: … [cited by applicant]
Rosenberg et al., “Combination Therapy with Metolazone and Loop Diuretics in Outpatients with Refactory Heart Failure: an Observational Study and Review of the Literature,” Cardiovascular Drugs and Therapy, Kluwer Acade… [cited by applicant]
Rui Geng et al., “Identification of Modifiable Risk Factors for Acute Kidney Injury After Coronary Artery Bypass Graft Surgery in an Asian Population,” The Journal of Thoracic and Cardiovascular Surgery, Apr. 2014, pp. … [cited by applicant]
S215 Ultra Low Profile Single Point Load Cell—Strain Guage Sensors and Load Cells, Ultra-Low Profile Single Point Load Cell—S215, http://smdsensors.com/detail_pgs/s215.htm 2005, 3 pages. [cited by applicant]
Se Won Oh et al., “Loop Diuretics in Clinical Practice”, Electrolytes & Blood Pressure, www.ncbi.nlm.nih.gov/pmc/articles/PMC4520883, printed Mar. 25, 2019, 6 pages. [cited by applicant]
Shepherd, “Measuring and Managing Fluid Balance”, Nursing Times, vol. 107, No. 28, pp. 12-16 (Jul. 19, 2011) 5 pages. [cited by applicant]
Solomon et al., Effects of Saline, Mannitol, and Furosemide on Acute Decreases in Renal Function Induced by Radiocontrast Agents, The New England Journal of Medicine, vol. 331: 1416-1420, Nov. 24, 1994, No. 21, 5 pages. [cited by applicant]
Stevens, Melissa A., MD et al., A Prospective Randomized Trial of Prevention Measures in Patients at High Risk for Contrast Nephropathy, Results of the P.R.I.N.C.E. Study, Journal of American College of Cardiology, vol.… [cited by applicant]
Stevenson et al., “Editorial Comment, Torrent or Torment From the Tubules?”, Challenge of the Cardiorenal Connections, Journal of the American College of Cardiology, vol. 45, No. 12, 2005, 4 pages. [cited by applicant]
Stickler et al., “A Sensor to Detect the Early Stages in the Development of Crystalline Proteus mirabilis Biofilm on Indwelling Bladder Catheters”, Journal of Clinical Microbiology, Apr. 2006, p. 1540-1542. [cited by applicant]
Teixeira et al., “Fluid Balance and Urine Volume are Independent Predictors of Mortality in Acute Kidney Injury”, Critical Care 17:R14 (2013) 11 pages. [cited by applicant]
Testani et al., “Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients with Heart Failure,” Circulation; Heart Failure, vol. 9. No. 1, 2016, 32 pages. [cited by applicant]
Thakar, “Perioperative Acute Kidney Injury,” Advances in Chronic Kidney Disease, vol. 20, No. 1, 2013, pp. 67-75. [cited by applicant]
Tricoli, “Miniaturized Bio-and Chemical-Sensors for Point-of-Care Monitoring of Chronic Kidney Diseases,” Sensors 2018, 18, 942; (Mar. 22, 2018) 18 pages. [cited by applicant]
Unknown Author, “Furosemide Drug Summary,” Prescriber's Digital Reference, pp. 1-31, 2016. [cited by applicant]
Vellinga et al., “Identification of Modifiable Risk Factors for Acute Kidney Injury After Cardiac Surgery,” The Netherlands Journal of Medicine, vol. 70, No. 10, Dec. 2012, pp. 450-454. [cited by applicant]
Wakelkamp et al., The influence of drug input rate on the development of tolerance to frusemide, Br. J. Clin. Pharmacol 1998, 46:479-487, 9 pages. [cited by applicant]
Weinstein et al., Potential deleterious Effect of Furosmide in Radiocontrast Nephropathy, Department of Medicine, Hadassah Univeristy Hospital, Mount Scopus, Jerusalem, Israel, Nephron 1992, 62: 413-415, pages. [cited by applicant]
Yeh et al., “Goal-directed diuresis: a case—control study of continuous furosemide infusion in critically ill trauma patients”, The Journal of Emergencies, Trauma, and Shock, 8(1): 34-38, 2015. [cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2005/008948 dated Oct. 3, 2006, 3 pages. [cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2007/021791 dated May 8, 2008, 7 pages. [cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/U20S07/009685 dated Jul. 18, 2008, 10 pages. [cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2007/009684 dated Jul. 21, 2008, 7 pages. [cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2008/007845 dated Sep. 17, 2008, 5 pages. [cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2008/007841 dated Sep. 18, 2008 4 pages. [cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2007/009683 dated Nov. 24, 2008, 6 pages. [cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2009/002739 dated Jun. 19, 2009, 4 pages. [cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2010/000137 dated Mar. 16, 2010, 8 pages. [cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2015/020196, dated Jun. 12, 2015, 5 pages. [cited by applicant]
Phillips et al., “Measurement of sodium ion concentration in undiluted urine with cation-selective polymeric membrane electrodes after the removal of interfering compounds”, Talanta, Elsevier, Amsterdam, NL, vol. 74, No… [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US24/46468, Applicant: Reprieve Cardiovascular, Inc., mailed Dec. 19, 2024, 15 pages. [cited by applicant]